Literature DB >> 6456889

Cefoperazone: spectrum of antibacterial activity and disc diffusion testing.

C Thornsberry, R N Jones.   

Abstract

Cefoperazone is a new cephalosporin with a very wide spectrum of antibacterial activity, including Enterobacteriaceae, Pseudomonas aeruginosa, staphylococci, streptococci (other than serological group D strains), Neisseria and Haemophilus species (including beta-lactamase positive strains) and some anaerobes. On testing more than 8700 clinical isolates, approximately 93% were inhibited by 16 micrograms/ml of cefoperazone, 95% by 32 micrograms/ml and 98% by 64 micrograms/ml. The drug is less active on Acinetobacter and group D streptococci. We recommend that a disc containing 75 micrograms of cefoperazone be used in the diffusion test with 'breakpoints' of less than or equal to 14 mm for resistant, 15-17 mm for intermediate, and greater than or equal to 18 mm for susceptible bacteria.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6456889     DOI: 10.2165/00003495-198100221-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  16 in total

1.  Comparative pharmacokinetics of cefoperazone and cefotaxime.

Authors:  H Lode; B Kemmerich; P Koeppe; D Belmega; H Jendroschek
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

2.  Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods.

Authors:  F A Drasar; W Farrell; A J Howard; C Hince; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

3.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

4.  Cefoperazone: absorption, excretion, distribution, and metabolism.

Authors:  K Shimizu
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

5.  Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats.

Authors:  L Balant; P Dayer; M Rudhardt; A F Allaz; J Fabre
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

6.  Single-dose pharmacokinetics of cefoperazone following intravenous administration.

Authors:  W A Craig
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

7.  Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; E H Gerlach; H M Sommers
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

8.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

9.  LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.

Authors:  G M Trager; G W White; V M Zimelis; A P Panwalker
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

10.  Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.